Using nasopharyngeal carriage as a marker of vaccine impact, pneumococcal colonization and its relation to invasive disease were examined in children, their parents, and older adults in the United Kingdom following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) and prior to 13-valent pneumococcal conjugate vaccine (PCV13).A cross-sectional observational study was conducted, collecting nasopharyngeal swabs from children aged 25 to 55 months who had previously received 3 doses of PCV7, their parents, and adults aged ≥65 years. Pneumococcal serotyping was conducted according to World Health Organization guidelines with nontypeable isolates further analyzed by molecular serotyping. A national invasive disease surveillance progra...
Background: Shifts in pneumococcal serotypes following introduction of 7-valent pneumococcal conjuga...
BackgroundWe sought to measure trends in Streptococcus pneumoniae carriage and antibiotic resistance...
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in The Netherlands in 2006 and was...
Using nasopharyngeal carriage as a marker of vaccine impact, pneumococcal colonization and its relat...
Using nasopharyngeal carriage as a marker of vaccine impact, pneumococcal colonization and its relat...
A serial cross-sectional study of nasopharyngeal carriage among adults aged 60 y or over was conduct...
In April 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the infant immunisa...
Streptococcus pneumoniae is both a common inhabitant of the human nasopharynx and a leading cause of...
We investigated the effect of the 7-valent pneumococcal conjugate vaccine (PCV7) programme in Englan...
A 10-year invasive pneumococcal disease (IPD) enhanced surveillance project in the Oxfordshire regio...
A 10-month longitudinal household study of pre-school children and their families was undertaken wit...
Streptococcus pneumoniae is the most frequently detected human pathogen in respiratory infections wi...
Background. In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine ...
We sought to determine the potential impact of seven-valent pneumococcal conjugate vaccine on the in...
BACKGROUND: The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal dis...
Background: Shifts in pneumococcal serotypes following introduction of 7-valent pneumococcal conjuga...
BackgroundWe sought to measure trends in Streptococcus pneumoniae carriage and antibiotic resistance...
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in The Netherlands in 2006 and was...
Using nasopharyngeal carriage as a marker of vaccine impact, pneumococcal colonization and its relat...
Using nasopharyngeal carriage as a marker of vaccine impact, pneumococcal colonization and its relat...
A serial cross-sectional study of nasopharyngeal carriage among adults aged 60 y or over was conduct...
In April 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the infant immunisa...
Streptococcus pneumoniae is both a common inhabitant of the human nasopharynx and a leading cause of...
We investigated the effect of the 7-valent pneumococcal conjugate vaccine (PCV7) programme in Englan...
A 10-year invasive pneumococcal disease (IPD) enhanced surveillance project in the Oxfordshire regio...
A 10-month longitudinal household study of pre-school children and their families was undertaken wit...
Streptococcus pneumoniae is the most frequently detected human pathogen in respiratory infections wi...
Background. In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine ...
We sought to determine the potential impact of seven-valent pneumococcal conjugate vaccine on the in...
BACKGROUND: The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal dis...
Background: Shifts in pneumococcal serotypes following introduction of 7-valent pneumococcal conjuga...
BackgroundWe sought to measure trends in Streptococcus pneumoniae carriage and antibiotic resistance...
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in The Netherlands in 2006 and was...